Repligen Corp. Files Definitive Proxy Statement (DEF 14A)

Ticker: RGEN · Form: DEF 14A · Filed: Apr 1, 2024 · CIK: 730272

Repligen Corp DEF 14A Filing Summary
FieldDetail
CompanyRepligen Corp (RGEN)
Form TypeDEF 14A
Filed DateApr 1, 2024
Risk Levellow
Pages14
Reading Time17 min
Key Dollar Amounts$7,929,275, $2,026,471, $3,743,430, $1,655,562, $1,661,482
Sentimentneutral

Sentiment: neutral

Topics: DEF 14A, Proxy Statement, Repligen Corp, RGEN, Corporate Governance

TL;DR

<b>Repligen Corp. has filed its Definitive Proxy Statement (DEF 14A) for the period ending May 16, 2024.</b>

AI Summary

REPLIGEN CORP (RGEN) filed a Proxy Statement (DEF 14A) with the SEC on April 1, 2024. Repligen Corp. filed a Definitive Proxy Statement (DEF 14A) on April 1, 2024. The filing covers the period ending May 16, 2024. The company's fiscal year ends on December 31st. Repligen Corp. is incorporated in Delaware. The company's principal business is Biological Products (No Diagnostic Substances).

Why It Matters

For investors and stakeholders tracking REPLIGEN CORP, this filing contains several important signals. This filing is a standard requirement for publicly traded companies to provide shareholders with information regarding annual meetings, director elections, and executive compensation. Shareholders will use this document to make informed decisions about company governance and voting matters.

Risk Assessment

Risk Level: low — REPLIGEN CORP shows low risk based on this filing. The filing is a routine DEF 14A, indicating no immediate material events or significant changes are being disclosed beyond standard corporate governance procedures.

Analyst Insight

Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to understand management's strategy and governance practices.

Key Numbers

  • 2024-04-01 — Filing Date (DEF 14A filing date)
  • 2024-05-16 — Reporting Period End Date (Conformed period of report)
  • 1231 — Fiscal Year End (Fiscal year end)

Key Players & Entities

  • REPLIGEN CORP (company) — Filer name
  • 0000730272 (company) — Central Index Key
  • DE (company) — State of Incorporation
  • 2836 (company) — Standard Industrial Classification
  • 41 SEYON STREET (company) — Business Address
  • WALTHAM (company) — Business Address City
  • MA (company) — Business Address State
  • 02453 (company) — Business Address Zip

FAQ

When did REPLIGEN CORP file this DEF 14A?

REPLIGEN CORP filed this Proxy Statement (DEF 14A) with the SEC on April 1, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by REPLIGEN CORP (RGEN).

Where can I read the original DEF 14A filing from REPLIGEN CORP?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by REPLIGEN CORP.

What are the key takeaways from REPLIGEN CORP's DEF 14A?

REPLIGEN CORP filed this DEF 14A on April 1, 2024. Key takeaways: Repligen Corp. filed a Definitive Proxy Statement (DEF 14A) on April 1, 2024.. The filing covers the period ending May 16, 2024.. The company's fiscal year ends on December 31st..

Is REPLIGEN CORP a risky investment based on this filing?

Based on this DEF 14A, REPLIGEN CORP presents a relatively low-risk profile. The filing is a routine DEF 14A, indicating no immediate material events or significant changes are being disclosed beyond standard corporate governance procedures.

What should investors do after reading REPLIGEN CORP's DEF 14A?

Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to understand management's strategy and governance practices. The overall sentiment from this filing is neutral.

How does REPLIGEN CORP compare to its industry peers?

Repligen Corp. operates in the biological products sector, focusing on products that are not diagnostic substances.

Are there regulatory concerns for REPLIGEN CORP?

As a publicly traded company, Repligen Corp. is subject to SEC regulations requiring the filing of proxy statements for shareholder meetings and votes.

Industry Context

Repligen Corp. operates in the biological products sector, focusing on products that are not diagnostic substances.

Regulatory Implications

As a publicly traded company, Repligen Corp. is subject to SEC regulations requiring the filing of proxy statements for shareholder meetings and votes.

What Investors Should Do

  1. Review executive compensation details and any proposed changes.
  2. Examine director nominations and qualifications.
  3. Identify any shareholder proposals and the company's recommended vote.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for public companies and does not represent a change from previous filings of the same type.

Filing Stats: 4,341 words · 17 min read · ~14 pages · Grade level 15.8 · Accepted 2024-04-01 16:17:36

Key Financial Figures

  • $7,929,275 — ony J. Hunt Chief Executive Officer $7,929,275 Jason K. Garland Chief Financial Of
  • $2,026,471 — K. Garland Chief Financial Officer $2,026,471 James R. Bylund Chief Operating Off
  • $3,743,430 — s R. Bylund Chief Operating Officer $3,743,430 Christine Gebski Senior Vice Presid
  • $1,655,562 — sident, Filtration and Chromatography $1,655,562 Ralf Kuriyel Senior Vice President,
  • $1,661,482 — e President, Research and Development $1,661,482 Olivier Loeillot President and Chie
  • $5,445,065 — resident and Chief Commercial Officer $5,445,065 Jon K. Snodgres Former Chief Financ
  • $2,170,932 — gres Former Chief Financial Officer $2,170,932 Long-term Equity Incentive Breakout f

Filing Documents

Security Ownership of Certain Beneficial Owners, Directors and Management

Security Ownership of Certain Beneficial Owners, Directors and Management 10 Proposal 1 – Election of Directors 12 Director Nominees 12 Occupations of Directors and Executive Officers 13 Biographical Information 14 Certain Relationships and Related Persons Transactions 18 Delinquent Section 16(a) Reports 18 Corporate Governance and Board Matters 19 Board Information 19 Director Independence 19 Board Leadership Structure 19 Executive Sessions 19 Director Nomination Policies 19 Shareholder Communication Policies 22 Director Attendance Policy 22 Stock Ownership Guideline and Insider Trading Policy 22 Code of Business Conduct & Ethics 23 The Board's Role in Risk Oversight 23 Sustainability – Environmental, Social and Governance Matters 23 Board Meetings and Committees 26 Audit Committee 26 Compensation Committee 26 Nominating and Corporate Governance Committee 27 Proposal 2 – Ratification of Selection of Our Independent Registered Public Accounting Firm 28 Audit and Non-Audit Fees 28 Audit Committee Report 29 Proposal 3 – Advisory Vote on Executive Compensation 30 Compensation Committee Report 30 Compensation Discussion and Analysis 31 2023 Leadership Changes 31 Business & Financial Highlights 2023 31 Compensation Philosophy 31 Compensation Objectives 31 Compensation Evaluation Processes 33

Executive Compensation

Executive Compensation 34 Equity Incentive Compensation 37 Clawback Policy 39 Other Compensation 40 Tax and Accounting Consideration 40 Compensation Risk Assessment 40

Executive Compensation Tables

Executive Compensation Tables 41 Director Compensation 56 Table of Contents General Annual Meeting Information 58 Record Date 58 Quorum 58 Voting Securities/Common Stock Outstanding 58 Voting Methods 58 Revoking Your Proxy 58 Effect of Abstentions and Broker Non-Votes 59 Votes Required for Adoption of Proposals 59 Cost of Proxy Solicitation 59 Additional Information 60 Submitting Shareholder Proposals 60 Other Business 60 Voting Proxies 60 Householding 60 Table of Contents PROXY STATEMENT SUMMARY We are furnishing this Proxy Statement and the related proxy materials in connection with the solicitation by our Board of Directors ("Board") of proxies to be voted at the 2024 Annual Meeting of Shareholders (the "Annual Meeting") and at any adjournment or postponement thereof. We are providing these materials to the holders of record of our Common Stock as of the close of business on March 18, 2024, and are first making available or mailing the materials on or about April 1, 2024. This summary highlights information contained elsewhere in the Proxy Statement. As this summary does not contain all the information that you should consider in connection with the Annual Meeting, we recommend that you read the entire Proxy Statement carefully before voting. References throughout the Proxy Statement to "Repligen Corporation", "Repligen", "we", "us", "our", or the "Company" refer to Repligen Corporation and its subsidiaries, taken as a whole, unless the context otherwise indicates. VOTING MATTERS Proposal Description Board Recommendation Proposal 1: Election of directors (page 12) We are asking our shareholders to elect each of the nine (9) directors identified below under "Our Director Nominees" , each to serve until the 2025 Annual Meeting of Shareholders. FOR each nominee Proposal 2: Ratification of the selection of the independent registered public accounting firm (page 28) We are aski

EXECUTIVE COMPENSATION HIGHLIGHTS

EXECUTIVE COMPENSATION HIGHLIGHTS Repligen's compensation philosophy is to provide compensation that will attract and retain high-performing talent in our industry, motivate the Company's executive officers to create long-term, enhanced shareholder value, provide a fair reward for robust effort and stimulate our executive officers' professional and personal growth. The Company believes that the compensation of its executive officers should align the executive officers' interests with those of the shareholders and focus executive officer behavior not only on the achievement of near-term corporate goals, but also on the achievement of long-term business objectives and strategies. For more on compensation philosophy see the section titled "Executive Compensation" on page 34. Compensation Earned The graphs below reflect the allocation of salary, cash incentive compensation and equity incentive compensation earned by the Company's CEO, Chief Financial Officer ("CFO"), President and Chief Commercial Officer ("CCO"), Chief Operating REPLIGEN CORPORATION 5 2024 PROXY STATEMENT SUMMARY Table of Contents Officer, Senior Vice President, Filtration & Chromatography, and Senior Vice President, Research & Development in 2023, all six of whom were serving as executive officers as of December 31, 2023 as well as our former CFO, Jon Snodgres, who retired from the Company effective October 31, 2023, and who ceased serving as CFO effective upon the hiring of the new CFO on September 25, 2023. We have elected to provide disclosure of compensation information for all of our 2023 executive officers, whom we refer to as NEOs throughout the Proxy Statement for simplicity. Additional NEO compensation detail and notes can be found in the "Executive Compensation Tables — 2023 Summary Compensation Table" on page 41. 2023 Summary Compensation Allocations REPLIGEN CORPORATION 6 2024 PROXY STATEMENT SUMMARY Table of Contents (1) The 5% of Mr. Garland's compensation in

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.